Prague Med. Rep. 2022, 123, 250-257
https://doi.org/10.14712/23362936.2022.23
Clinical Course of COVID-19 and Cycle Threshold in Patients with Haematological Neoplasms
References
1. 2021) Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: A report from the Argentine Society of Hematology. Medicina (B. Aires) 81(4), 536–645.
, A. L., García, M. J., Rolón, J. M., Olmedo, J., Laviano, J., Burgos, R., Caeiro, G., Remaggi, G., Raña, P., Paoletti, M., González, C. M., Fernández, I., Pavlovsky, A., Perusini, M. A., Rodriguez, A., Guanchiale, L., Carvani, A., Mandrile, L., Figueroa, F., Vicente Reparaz, A., Fragapane Mathus, P. N., Garate, G., Fauque, M. E., Kantor, G., Cruset, S., Gonzalez Lorch, J. S., Szelagowski, M., Giarini, M. P., Oliveira, N., García, M. C., Ventriglia, M. V., Pereyra, P. H., Gutierrez, D. R., Kusminsky, G., Troccoli, J., Freitas, M. J., Cranco, S., Del V Sanchez, N., Rey, I., Funes, M. E., Jarchum, S., Freue, J., Miroli, A., Guerrero, O., López Ares, L., Campestri, R., Bove, V., Salinas, G. N., Cabrejo, M., Milone, J. H., Zabaljauregui, S., Gotta, D., Dupont, J. C., Stemmelin, G. (
2. Buenos Aires Ciudad – Gobierno de la Ciudad Autónoma de Buenos Aires (2021) Protocolo de Manejo de Casos SOSPECHOSOS y Confirmados de Coronavirus (COVID-19). Retrieved January 30, 2022, available at: https://www.buenosaires.gob.ar/sites/gcaba/files/id_0_-_protocolo_de_manejo_frente_a_casos_sospechosos_y_confirmados_de_covid-19_130122_0.pdf
3. 2020) Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N. Engl. J. Med. 383(23), 2291–2293.
< , B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., Adhikari, U. D., Winkler, M. L., Mueller, A. A., Hsu, T. Y.-T., Desjardins, M., Baden, L. R., Chan, B. T., Walker, B. D., Lichterfeld, M., Brigl, M., Kwon, D. S., Kanjilal, S., Richardson, E. T., Jonsson, A. H., Alter, G., Barczak, A. K., Hanage, W. P., Yu, X. G., Gaiha, G. D., Seaman, M. S., Cernadas, M., Li, J. Z. (https://doi.org/10.1056/NEJMc2031364>
4. 2020) The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types. Cancer 126(14), 3192–3201.
< , H., Borghaei, H., Orlowski, R. Z., Subklewe, M., Roboz, G. J., Zugmaier, G., Kufer, P., Iskander, K., Kantarjian, H. M. (https://doi.org/10.1002/cncr.32909>
5. 2021) Preanalytical issues and cycle threshold values in SARS-CoV-2 real-time RT-PCR testing: Should test results include these? ACS Omega 6(10), 6528–6536.
< , I., Alidjinou, E. K., Ogiez, J., Pagneux, Q., Miloudi, S., Benhalima, I., Ouafi, M., Sane, F., Hober, D., Roussel, A., Cambillau, C., Devos, D., Boukherroub, R., Szunerits, S. (https://doi.org/10.1021/acsomega.1c00166>
6. 2020) Is higher viral load in SARS-CoV-2 associated with death? Am. J. Trop. Med. Hyg. 103(5), 2019–2021.
< , K. S., Passarelli, V. C., Bellei, N. (https://doi.org/10.4269/ajtmh.20-0954>
7. 2021) Epidemiologic characteristics associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-based test results, real-time reverse transcription polymerase chain reaction (rRT-PCR) cycle threshold values, subgenomic RNA, and viral culture results from university testing. Clin. Infect. Dis. 73(6), e1348–e1355.
< , L., Lee, C., Pray, I. W., Cole, D., Bigouette, J. P., Abedi, G. R., Bushman, D., Delahoy, M. J., Currie, D. W., Cherney, B., Kirby, M. K., Fajardo, G. C., Caudill, M., Langolf, K., Kahrs, J., Zochert, T., Kelly, P., Pitts, C., Lim, A., Aulik, N., Tamin, A., Harcourt, J. L., Queen, K., Zhang, J., Whitaker, B., Browne, H., Medrzycki, M., Shewmaker, P. L., Bonenfant, G., Zhou, B., Folster, J. M., Bankamp, B., Bowen, M. D., Thornburg, N. J., Goffard, K., Limbago, B., Bateman, A., Tate, J. E., Gieryn, D., Kirking, H. L., Westergaard, R. P., Killerby, M. E.; CDC COVID-19 Surge Laboratory Group (https://doi.org/10.1093/cid/ciab303>
8. IDSA (2021) IDSA statement on the use of CT values final. (n.d.) Retrieved April 20, 2022, available at: https://www.idsociety.org/globalassets/idsa/public-health/covid-19/idsa-amp-statement.pdf
9. 2020) Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur. J. Clin. Microbiol. Infect. Dis. 39(6), 1059–1061.
< , B., Le Bideau, M., Andreani, J., Hoang, V. T., Grimaldier, C., Colson, P., Gautret, P., Raoult, D. (https://doi.org/10.1007/s10096-020-03913-9>
10. 2020) COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: A prospective cohort study. Lancet Oncol. 21(10), 1309–1316.
< , L. Y. W., Cazier, J.-B., Starkey, T., Briggs, S. E. W., Arnold, R., Bisht, V., Booth, S., Campton, N. A., Cheng, V. W. T., Collins, G., Curley, H. M., Earwaker, P., Fittall, M. W., Gennatas, S., Goel, A., Hartley, S., Hughes, D. J., Kerr, D., Lee, A. J. X., Lee, R. J., Lee, S. M., Mckenzie, H., Middleton, C. P., Murugaesu, N., Newsom-Davis, T., Olsson-Brown, A. C., Palles, C., Powles, T., Protheroe, E. A., Purshouse, K., Sharma-Oates, A., Sivakumar, S., Smith, A. J., Topping, O., Turnbull, C. D., Várnai, C., Briggs, A. D. M., Middleton, G., Kerr, R.; UK Coronavirus Cancer Monitoring Project Team (https://doi.org/10.1016/S1470-2045(20)30442-3>
11. 2021) Impact of rituximab on COVID-19 outcomes. Ann. Hematol. 100(11), 2805–2812.
< , H., Lancman, G., Gabrilove, J. (https://doi.org/10.1007/s00277-021-04662-1>
12. 2021) Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study. PLoS One 16(1), e0245382.
< , I., Forde, D., Zelek, W., Tyson, L., Chichester, L., Palmer, N., Jones, R., Morgan, B. P., Moore, C. (https://doi.org/10.1371/journal.pone.0245382>
13. 2020) Ultra-sensitive serial profiling of SARS-CoV-2 antigens and antibodies in plasma to understand disease progression in COVID-19 patients with severe disease. Clin. Chem. 66(12), 1562–1572.
< , A. F., Maley, A. M., Wu, C., Gilboa, T., Norman, M., Lazarovits, R., Mao, C.-P., Newton, G., Chang, M., Nguyen, K., Kamkaew, M., Zhu, Q., Gibson, T. E., Ryan, E. T., Charles, R. C., Marasco, W. A., Walt, D. R. (https://doi.org/10.1093/clinchem/hvaa213>
14. 2021) Viral dynamics and real-time RT-PCR Ct values correlation with disease severity in COVID-19. Diagnostics (Basel) 11(6), 1091.
< , A. A., Tirupathi, R., Sule, A. A., Aldali, J., Mutair, A. A., Alhumaid, S., Muzaheed, Gupta, N., Koritala, T., Adhikari, R., Bilal, M., Dhawan, M., Tiwari, R., Mitra, S., Emran, T. B., Dhama, K. (https://doi.org/10.3390/diagnostics11061091>
15. 2020) SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. Cancer Cell 38(5), 661–671.e2.
< , L. F., Brar, G., Pinheiro, L. C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J. L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C. B., Rand, J. H., Cushing, M. M., Walsh, T. J., Cooke, J., Safford, M. M., Loda, M., Satlin, M. J. (https://doi.org/10.1016/j.ccell.2020.09.007>
16. 2020) Outcomes of patients with hematologic malignancies and COVID-19: A report from the ASH Research Collaborative Data Hub. Blood Adv. 4(23), 5966–5975.
< , W. A., Neuberg, D. S., Thompson, J. C., Tallman, M. S., Sekeres, M. A., Sehn, L. H., Anderson, K. C., Goldberg, A. D., Pennell, N. A., Niemeyer, C. M., Tucker, E., Hewitt, K., Plovnick, R. M., Hicks, L. K. (https://doi.org/10.1182/bloodadvances.2020003170>